Evidence map›Paper›PMID 40304302›Full record

ArticleMolecular pharmaceutics2025

Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC.

Carmine P Cerrato, Martin Krkoška, Yue Sun, Judit Liaño-Pons, Qi Ying Neo, Thibault Vosselman, Mohammad Alzrigat, Borek Vojtěšek, David P Lane, Marie Arsenian Henriksson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Reversible Nucleolar Complex Coacervation by Short Cationic Peptides.Journal of the American Chemical Society · 2026
    Article
  2. Review
  3. Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carmine P CerratoDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Martin KrkoškaDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Yue SunCentre for Sustainable Materials, School of Materials Science and Engineering, Nanyang Technological University (NTU), 50 Nanyang Avenue, Singapore 637553, Singapore.
Judit Liaño-PonsDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.ORCID 0000-0001-8097-4750
Qi Ying NeoCentre for Sustainable Materials, School of Materials Science and Engineering, Nanyang Technological University (NTU), 50 Nanyang Avenue, Singapore 637553, Singapore.ORCID 0000-0001-9602-3490
Thibault VosselmanDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Mohammad AlzrigatDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Borek VojtěšekResearch Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
David P LaneDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Marie Arsenian HenrikssonDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Ali MiserezCentre for Sustainable Materials, School of Materials Science and Engineering, Nanyang Technological University (NTU), 50 Nanyang Avenue, Singapore 637553, Singapore.ORCID 0000-0003-0864-8170
Michael LandrehDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.ORCID 0000-0002-7958-4074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracellular delivery is a bottleneck in the development of therapeutic peptides and proteins. Here, we demonstrate the efficient delivery of omoMYC, the first MYC inhibitor in clinical trials, using HB

Indexed as

Antineoplastic AgentsCell-Penetrating PeptidesDrug Delivery SystemsProto-Oncogene Proteins c-mycApoptosisCell Line, TumorCell ProliferationHEK293 CellsHeLa CellsHumansProtein EngineeringAntineoplastic AgentsCell-Penetrating PeptidesProto-Oncogene Proteins c-mycdrug deliveryliquid−liquid phase separationprotein engineering

Identifiers

PMID40304302
PMCPMC12135055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.